Motrim (Trimethoprim)

Trimethoprim, the active ingredient in Motrim, is a dihydrofolate reductase inhibitor presented as a tablet for oral use. It treats urinary tract infections, including acute uncomplicated cystitis, in adult patients.

GNH USA supplies Motrim as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Motrim is an antibacterial agent used to treat infections of the urinary tract and related conditions. - Urinary tract infections: eradicates susceptible bacteria and relieves urinary symptoms. - Acute uncomplicated cystitis: provides bacterial clearance and rapid symptom resolution. - Lower urinary tract infections (e.g., urethritis): reduces bacterial load and prevents progression.

Common side effects are generally mild and reversible.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Vomiting: occasional emesis. - Loss of appetite: reduced desire to eat. - Rash: mild skin erythema. - Diarrhea: loose stools. - Headache: transient head discomfort.

Serious or Rare Side Effects: - Stevens‑Johnson syndrome: severe skin reaction requiring immediate medical attention. - Agranulocytosis or aplastic anemia: marked reduction in blood cell production. - Elevated liver enzymes: signs of hepatic stress. - Renal toxicity: impaired kidney function. - Severe allergic reactions: anaphylaxis or angioedema. - Hemolytic anemia in G6PD deficiency: destruction of red blood cells.

Before prescribing Motrim, clinicians should consider patient‑specific factors and monitor for adverse events. - Renal function: assess kidney status and adjust dose if necessary. - Hypersensitivity: discontinue if rash, pruritus, or systemic allergic signs develop. - Folate deficiency: monitor patients with low folate levels, especially those on long‑term therapy. - Pregnancy: use only if the potential benefit justifies the potential risk. - Known allergy to trimethoprim: avoid use. - Store at below 25°C: keep in the original pack, protect from moisture.

Trimethoprim may interact with several medicines, altering efficacy or safety.

Major Interactions (Avoid): - Warfarin: increased anticoagulant effect, risk of bleeding. - Methotrexate: heightened toxicity due to additive folate antagonism. - Phenytoin: accelerated clearance of trimethoprim, reducing effectiveness. - Trimethoprim‑sulfamethoxazole: duplicate therapy, unnecessary exposure.

Moderate Interactions (Monitor Closely): - NSAIDs: potential for reduced renal perfusion. - ACE inhibitors or ARBs: increased risk of hyperkalemia. - Loop or thiazide diuretics: electrolyte disturbances may be amplified. - Oral contraceptives: possible reduction in contraceptive efficacy. - Allopurinol: may increase risk of rash.